-
中国原研CDK4/6抑制剂Bireociclib显著延长HR+/HER2-晚期乳腺癌PFS期丨肿瘤研究展播
研究名称：Bireociclib plus fulvestrant for HR+/HER2advanced female breast cancer prog...
热度10202026-03-11 -
新型高选择性CDK4/6抑制剂为多线治疗失败乳腺癌患者带来持久缓解丨肿瘤研究展播
研究名称：An open-label, single-arm, multicenter, phase II trial of bireociclib as mo...
热度10092026-03-11 -
中国原研脂质体为多线治疗失败的mTNBC带来生存新希望丨肿瘤研究展播
研究名称：Intravenous liposomal irinotecan in metastatic triple-negative breast cance...
热度11402026-03-11 -
既往内分泌治疗失败的HR+/HER2-晚期乳腺癌患者有效治疗新选择丨肿瘤研究展播
研究名称：Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or ...
热度11252026-03-11 -
ADC新药单药疗效比肩四药联合丨肿瘤研究展播
研究名称：Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in w...
热度12662026-03-11 -
打通基础-临床壁垒，逆转最“毒”乳腺癌免疫耐药困境丨肿瘤研究展播
研究名称：Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-neg...
热度12532026-03-11 -
量化呼吸扰动：质子治疗乳腺癌的精准“度量衡”丨肿瘤研究展播
研究名称：Particle therapy for breast cancer发表期刊：PTCOG63 口头报告通讯作者：朱健第一作者：刘源主要作者单位：山东第...
热度11932026-03-11 -
新型HER2双表位ADC药物疗效可期丨肿瘤研究展播
研究名称：Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Hum...
热度11272026-03-11 -
早期三阴性乳腺癌治疗迈向“蒽环紫杉铂类三驾马车”新时代丨肿瘤研究展播
研究名称：Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in w...
热度12582026-03-11 -
AI全程驱动，验证SNF分型指导HR+/HER2-乳腺癌精准治疗丨肿瘤研究展播
研究名称：Precision treatment with artificial intelligence assisted subtyping enhance...
热度9972026-03-11
